PRDM16-DT

Across TCGA pan-cancer cohorts, PRDM16-DT RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of PRDM16-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRDM16-DT RNA is repressed in tumor relative to normal tissue. In most cancer types PRDM16-DT is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and BLCA are the cancer types where PRDM16-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRDM16-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	−4.510	<.001	12	view →
KIRP	Male	All	−5.237	<.001	11	view →
BLCA	All	III,IV	−0.511	<.001	11	view →
THCA	Male	IV	−3.456	<.001	10	view →
LUAD	Male	III,IV	−1.441	<.001	9	view →
LUSC	Female	II,III,IV	−1.412	<.001	8	view →
BRCA	All	II,III,IV	−0.695	<.001	8	view →
COAD	All	II,III,IV	−0.261	<.001	8	view →
KICH	Male	All	−2.482	<.001	7	view →
UCEC	All	All	−0.682	.035	4	view →
LIHC	All	All	+0.183	.003	4	view →
CHOL	All	All	+1.081	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

PRDM16-DT–KIRC

Open the KIRC breakdown →